Previous studies suggest autophagy inhibition represents a viable therapeutic approach to overcome resistance of BRAFV600E‐mutant brain tumour and melanoma cells to BRAF inhibition.22, 24 To determine the role of autophagy within MEKi‐resistant melanoma cells, A375 cells continuously treated with 16 nmol L−1 trametinib for 42 days were further treated for 48 h with trametinib alone or in combination with 5 μmol L−1 PIK‐III, 10 μmol L−1 CQ or 5 μmol L−1 THC. The gene discussed is BRAF; the disease is brain neoplasm.